research How useful is ritlecitinib in alopecia areata?
Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
Search
for
Sort by
Research
600-630 / 1000+ results
research Inhibition of rat α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
research Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
research Optimizing finasteride chemoprevention
research 5 alpha-reductase and finasteride in pattern alopecia and acne.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System
JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
research Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus
Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Finasteride to treat recurrent priapism in sickle cell anemia
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Development of a Liquid Chromatography/Mass Spectrometry-Based Inhibition Assay for the Screening of Steroid 5-α Reductase in Human and Fish Cell Lines
A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.
research Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
research ChemInform Abstract: Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α‐Reductase Inhibitor.
A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
research Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, In Vitro, and In Silico Studies
New compounds show promise as nonsteroidal treatments for hair loss.
research Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon α 2a therapy for chronic hepatitis C virus infection
Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.
research A Novel Role of IL-17+ Cell Subsets in Ross River Virus-Induced Arthritic Disease
Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Pharmacophore Modeling and Three Dimensional Database Searching for Drug Design Using Catalyst: Recent Advances
The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
research Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
Using finasteride or dutasteride may cause long-lasting erectile dysfunction.
research Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research Inhibition of 5α-Reductase Activity in SZ95 Sebocytes and HaCaT Keratinocytes In Vitro
The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
research Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing
Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.